The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers-Reference-Cited by-同舟云学术

The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers

Published:2019-04 Issue:4 Volume:7 Page:1261-1270
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Shim Ji-Su,Yun James,Kim Mi-Yeong,Chung Soo Jie,Oh Ji Hyun,Kang Dong-Yoon,Jung Jae-Woo,Cho Sang-Heon,Kang Hye-Ryun

Funder

Korean Association of Internal Medicine Research

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference44 articles.

1. Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions;Wang;Curr Opin Allergy Clin Immunol,2016

2. HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy;Jung;Tohoku J Exp Med,2014

3. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout;Frampton;Drugs,2015

4. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan;Yang;JAMA Intern Med,2015

5. Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation;Sukasem;Asian Pac J Allergy Immunol,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review;Drugs;2023-10-11

2. HLA‐A*24:02 increase the risk of allopurinol‐induced drug reaction with eosinophilia and systemic symptoms in HLA‐B*58:01 carriers in a Korean population; a multicenter cross‐sectional case‐control study;Clinical and Translational Allergy;2022-09

3. Advances and highlights in T and B cell responses to drug antigens;Allergy;2021-10-15

4. Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis;Frontiers in Pharmacology;2021-04-26

5. Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in South Korea;Frontiers in Medicine;2021-02-22